文献速递泌尿生殖MRUS

随访活检中前列腺MRI可见病灶是主动监测期间组织病理学升级的风险因素

The presence of prostate MRI-visible lesions at follow-up biopsy as a risk factor for histopathological upgrading during active surveillance.
PubMed 文献 · Abdom Radiol (NY) · 2025-03-12

前瞻性研究纳入240例低危前列腺癌主动监测患者,评估mpMRI可见病灶(PI-RADS 4-5)及常用生物标志物预测再活检疾病升级的能力;总体升级率41.2%(99/240),PI-RADS 4或5患者升级率更高(77%),MRI敏感度77.7%、特异度83.6%。

要点

  • PI-RADS 4或5病灶、PSA密度>0.15 ng/mL/cm3且首次活检3+/12阳性针的患者再活检临床显著前列腺癌概率达92.4%。
  • mpMRI可见病灶、PSA密度和首次活检3+/12阳性针是再活检疾病升级的良好预测因素。
  • 主动监测患者中PI-RADS 4或5者升级率77%,总体升级率41.2%(99/240)。

核心结论

  • 主动监测患者若存在PI-RADS 4或5病灶、PSA密度>0.15 ng/mL/cm3且首次活检3+/12阳性针,再活检发现显著前列腺癌的概率高。

研究设计与样本

  • 前瞻性研究,经机构审查委员会(IRB)批准,纳入2014年3月至2020年12月登记于本中心主动监测程序的连续低危、低级别、局限性前列腺癌患者,共240例。
  • 所有符合条件患者在初次活检至少3个月后接受mpMRI,入组后12个月内接受MRI靶向经直肠超声引导再活检;mpMRI由经验丰富的放射科医师采用PI-RADS v2分类评估。
  • 排除既往前列腺手术、激素治疗、mpMRI或经直肠超声引导活检禁忌者。

诊断标准与关键数值

  • mpMRI可见病灶定义为PI-RADS 4-5;再活检MRI敏感度77.7%、特异度83.6%。
  • PI-RADS 4或5患者升级率77%,总体升级率41.2%(99/240)。
  • 预测模型:PI-RADS 4或5、PSA密度>0.15 ng/mL/cm3且首次活检3+/12阳性针的患者再活检临床显著前列腺癌概率为92.4%。

临床应用与阅片要点

  • 主动监测患者随访再活检前,应结合mpMRI PI-RADS评分、PSA密度和首次活检阳性针数评估升级风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To prospectively determine the ability of visible lesions on multiparametric MRI (PI-RADS 4-5) and commonly used biomarkers to predict disease upgrading on rebiopsy in men with low-risk prostate cancer (PCa) enrolled in active surveillance (AS).

MATERIALS AND METHODS: For this prospective study, approved by the Institutional Review Board (IRB), we selected consecutive patients with low-risk, low-grade, and localized prostate cancer (PCa) from our active surveillance (AS) program, who were enrolled between March 2014 and December 2020. Patients who had undergone previous prostate surgery, hormonal treatment, had contraindications for mpMRI, or transrectal ultrasound-guided (TRUS) biopsy were excluded from this study. All eligible patients underwent mpMRI at least 3 months after the initial biopsy, followed by MRI-targeted TRUS-guided re-biopsy within 12 months after enrollment. The mpMRI studies were evaluated by an experienced radiologist using the PI-RADS v2 classification. Statistical significance was determined by comparing the results from the MRI with the pathology data from rebiopsy.

RESULTS: There were 240 patients included. Overall upgrading rate was 41.2% (99/240), higher among patients classified as PIRADS 4 or 5 (77%). MRI sensitivity was 77.7% and specificity was 83.6% on re-biopsy. Visible lesion on mpMRI, PSA density and 3 + /12 positive cores at the first biopsy were good predictors of disease upgrade on rebiopsy. On our predictive model, patients with PI-RADS 4 or 5, PSA density > 0.15 ng/mL/cm3, and 3 + /12 positive cores at first biopsy had 92.4% chance of having clinically significant PCa.

CONCLUSION: Patients in AS with PI-RADS 4 or 5 lesions, PSA density > 0.15 ng/mL/cm3 and 3 + /12 positive cores at first biopsy have a high probability of having significant PCa on re-biopsy.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Viana PCC, Pinto PVA, Horvat N, et al. The presence of prostate MRI-visible lesions at follow-up biopsy as a risk factor for histopathological upgrading during active surveillance. Abdom Radiol (NY). 2025. PMID: 40072539. doi:10.1007/s00261-025-04871-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。